The activity of NK cells and interferon-γ levels were increased in the circulation, indicating augmentation of antitumor immunity by GEN0101. This trial showed not only the safety and tolerability but also the significant antitumor effect of GEN0101, suggesting that GEN0101 might be a promising new drug for patients with advanced melanoma.
In conclusions, intratumoral and subcutaneous injections of GEN0101 were well tolerated and feasible to use. The study is registered at UMIN Clinical Trials Registry, number UMIN000017092.